Accent Microcell Limited

Accent Microcell Limited (ACCENTMIC) – Company Profile (H2 & FY26)

Business overview Accent Microcell Limited manufactures pharmaceutical excipients, focusing on cellular-based products and other excipient derivatives. Its main core product is Microcrystalline Cellulose (MCC), alongside MCC spheres, croscarmellose sodium, and Magnesium Stearate. These products find applications across pharmaceutical, nutraceutical, food bakery, dairy, welding electrodes, cosmetic, and personal care industries. The company serves customers in over 75 countries, utilizing a distribution model to cater to global and domestic markets.

Key facts

• Incorporated in 2012 and listed in 2023.
• Operates two manufacturing facilities at Pirana and Dahej SEZ in Gujarat, India, with a combined installed capacity of approximately 10,000 metric tons (for MCC equivalent products).
• Exports accounted for roughly 63% of total revenue in FY26, an increase from 53% in FY25, indicating a robust international presence.
• The company reported total sales volume of 15,000 metric tons in FY26, with 25-30% originating from traded volumes.
• It has 400 global team members and holds various international certifications, including XPAC, GMP, ISO, FSSI, HSCCP, and USDMF for its Dahej SEZ unit.
• Promoters include Mr. Vasant Patel (Chairman), Mr. Ghanshyam Patel (Managing Director and CFO), and Mr. Nitin Patel (Executive Director).

Recent developments (from concall / AR)

• The company is expanding its manufacturing capacity with Unit 3, planned in phases, with Phase 1 focusing on premium excipient products and Phase 2 on MCC.
• Unit 3 Phase 1, initially delayed due to abnormal monsoons and regulatory approvals, is now expected to commence commercial production by end of June 2026.
• Accent Microcell is developing India's first wood pulp-based Carboxymethyl Cellulose (CMC) and Carboxymethyl Cellulose Spheres (CCS), with Phase 1 of Unit 3 targeting a capacity of 2,400 tons for CCS.
• The company reported an order book of approximately 4,000 metric tons for MCC and 3-4 months of orders for its premium products in both export and domestic markets.
• Management is actively working to reduce working capital days and plans to gradually increase direct sales channels from the current 15% to improve margins.

Key risks flagged by management

• Delays in commercialization of Unit 3 Phase 1 due to external factors, including two back-to-back abnormal monsoons and ongoing regulatory and environmental approvals for the greenfield project.
• Management cited geopolitical tensions and external uncertainties as potential challenges affecting operations.
• Dependency on continuous regulatory approvals for new units and products, which can cause delays beyond management control.

Pros

• Strong focus on high-value, premium excipient products like SMCC and MCC Spheres, which contribute to higher blended profit margins.
• Significant export market presence (63% of revenue in FY26 across 75+ countries) provides a natural hedge against currency devaluation.
• Pioneering new technologies, such as India's first wood pulp-based CMC and CCS, offers a competitive advantage and diversification.

Cons

• Significant delays in Unit 3 commercialization due to regulatory and environmental issues have pushed timelines for new capacities.
• Reliance on trading activity for 25-30% of sales volume in FY26, which yields lower profit margins (4-5%) compared to manufactured products.
• High trade receivables (approximately 90 crores in FY26) indicate a stretched working capital cycle, though management is addressing it.